Drug Trial Radar · NCT07389044
A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
88
Planned (sponsor's estimate)
Start
Feb 20, 2026
Primary completion
Apr 30, 2027
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- IntegerBioIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will examine the safety and tolerability of single and multiple doses of IB-001 in two parts: Part A: SAD study in approximately 50 Healthy Volunteers (HV). Part B: MAD study in approximately 30 adult participants living with Chronic Hepatitis B (CHB). A separate exploratory, open-label, single-dose cohort (Part C) will evaluate pegylated interferon alfa-2a in HVs for translational benchmarking against IB-001.
Conditions
- Chronic Hepatitis B Virus Infection
Interventions
IB-001Drug
IB-001 is an investigational product targeting the type I IFN (IFN-I) signaling pathway. Subcutaneous (SC) injectable formulation; single doses in HVs (Part A) and weekly doses for 4 weeks in CHB participants (Part B). Exact dose levels recommended by SRC.
PlaceboOther
Sodium Chloride (NaCl) 0.9 % administered subcutaneously as a single dose (Part A) and weekly dose for 4 weeks (Part B).
Peginterferon Alfa-2ADrug
Peginterferon alfa-2a administered subcutaneously as a single dose (Part C) at a dose of 180 mcg/0.5 mL solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A and Part B: Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs).Time frame: Through Day 29 (Part A), through Day 64 (Part B).
- Part A and Part B: Number of Participants with Adverse Events (AEs) by SeverityTime frame: Through Day 29 (Part A), through Day 64 (Part B)
- Part A and Part B: Number of Participants with Adverse Events (AEs) of Special Interest (AESIs)Time frame: Through Day 29 (Part A), through Day 64 (Part B)
- Part A and Part B: Number of Participants with Clinically Significant Changes in Laboratory ParametersTime frame: Through Day 15 (Part A), through Day 64 (Part B)
- Part A and Part B: Number of Participants with Clinically Significant Changes in Vital Signs.Time frame: Through Day 15 (Part A), through Day 64 (Part B)
- Part A and Part B: Number of Patients with Clinically Significant Changes in Cardiac Parameters.Time frame: Through Day 15 (Part A), through Day 64 (Part B)
Locations
5 sites in 4 countries. Site status is shown where the registry gives one.
Prince of Wales Hospital
Hong Kong, Hong Kong · Recruiting
Queen Mary Hospital
Hong Kong, Hong Kong · Recruiting
Arensia Exploratory Medicine Chisinau
Chisinau, Moldova · Recruiting
New Zealand Clinical Research
Auckland, Auckland, New Zealand · Recruiting
Arensia Exploratory Medicine
Kyiv, Ukraine · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.